Table 1.
Basic characteristics of included studies
| Author | Year | Country | Study design | Time intervals and Sample size | stage | NCT | endpoint | NOSa |
|---|---|---|---|---|---|---|---|---|
| Liu et al. | 2018 | China | R |
<4weeks: 111 4-6weeks: 48 >6weeks: 17 |
cT2-4, N0-3 |
SOX; XELOX | pCR; OS; DFS | 7 |
| Wu et al. | 2019 | China | R |
<=4weeks: 70 5-6weeks: 103 >6weeks: 56 |
cT3/4, N+ |
SOX; XELOX | OS; DFS | 7 |
| Juan et al. | 2020 | Spain | R |
<4weeks: 18 4-6weeks: 26 >6weeks: 16 |
cT2-4, N0-3 |
ECF; EOX; FLOT | DS; OS | 7 |
| Wang et al. | 2020 | China | R |
<=21days: 49 22-28days: 93 29-35days: 108 36-42days:84 42-84days: 92 |
cT0-4, N0-3 |
SOX; XELOX | pCR; OS; DFS | 7 |
| Augustinas et al. | 2021 | Lithuania | R |
<=30days:70 31-43days: 138 >=44days:72 |
cT2-T4, N+ |
FLOT; FP; ECX; EOX | mPR; OS; DFS | 8 |
Abbreviations: R Retrospective study, SOX S-1 and oxaliplatin, XELOX Capecitabine and oxaliplatin, ECF Epirubicin, cisplatin and 5-FU, Eox Epirubicin, oxaliplatin and capecitabine, FLOT Docetaxel, oxaliplatin, leucovorin and 5-fluoracil, FP Fluoropyrimidine and platinum-based doublet, ECX Epirubicin, cisplatin, capecitabine
aThe Newcastle Ottawa Quality Assessment Scale (NOS)